BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29672893)

  • 1. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
    Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
    Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
    Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
    Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
    Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
    Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
    Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
    [No Abstract]   [Full Text] [Related]  

  • 5. Postoperative Surveillance in Older Adults With T1N0M0 Low-risk Papillary Thyroid Cancer.
    Pradhan MC; Kazaure HS; Wang F; Zambeli-Ljepovic A; Perkins JM; Stang MT; Scheri RP
    J Surg Res; 2021 Aug; 264():37-44. PubMed ID: 33765509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
    Tian T; Huang R; Liu B
    Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Risk Stratification in the Follow-Up of Children and Adolescents with Differentiated Thyroid Cancer.
    Zanella AB; Scheffel RS; Nava CF; Golbert L; Laurini de Souza Meyer E; Punales M; Gonçalves I; Dora JM; Maia AL
    Thyroid; 2018 Oct; 28(10):1285-1292. PubMed ID: 30129889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
    Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
    Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
    Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
    Cuéllar DI; De Los Reyes A; Llamas-Olier A
    Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma.
    Song E; Ahn J; Song DE; Kim WW; Jeon MJ; Sung TY; Kim TY; Chung KW; Kim WB; Shong YK; Hong SJ; Lee YM; Kim WG
    Clin Endocrinol (Oxf); 2020 Apr; 92(4):358-365. PubMed ID: 31630423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic Risk Stratification in Stage I Papillary Thyroid Cancer Patients Younger Than 45 Years of Age.
    Sung TY; Cho JW; Lee YM; Lee YH; Kwon H; Jeon MJ; Kim WG; Choi YJ; Song DE; Chung KW; Yoon JH; Hong SJ
    Thyroid; 2017 Nov; 27(11):1400-1407. PubMed ID: 28847226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
    Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
    Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.
    Sung TY; Jeon MJ; Lee YH; Lee YM; Kwon H; Yoon JH; Chung KW; Kim WG; Song DE; Hong SJ
    J Clin Endocrinol Metab; 2017 Mar; 102(3):793-800. PubMed ID: 27809646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with Papillary Thyroid Cancer in South Korea.
    Lee SG; Lee WK; Lee HS; Moon J; Lee CR; Kang SW; Jeong JJ; Nam KH; Chung WY; Jo YS; Lee J
    Thyroid; 2017 Feb; 27(2):174-181. PubMed ID: 27750028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
    Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
    Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.